Anti-atopic cream

Abstract

The present invention relates to an anti-atopic cream comprising: a first component comprising Houttuynia cordata, Acori gramineri Rhizoma, Saposhnikoviae Radix, Astragalus membranaceus Radix, Eriobotryae Folium, Sophorae flavescentis Radix, Saururus chinensis, Phellodendron bark, Centella asiatica, Arisaematis Rhizoma and Aster yomena; and a second component comprising glycerol, a caprylic or capric triglyceride, sunflower seed oil, butylene glycol, butylene glycol dicaprylate or dicaprate, macadamia seed oil, polyglyceryl-3 methylglucose distearate, PEG-4 olivate, meadowfoam seed oil, dimethicone, cetyl ethylhexanoate, oxidized corn oil, cetearyl alcohol, tocopheryl acetate, glyceryl acrylate or acrylic acid copolymer, stearyl glycyrrhetinate, sodium chloride, sodium acrylate or sodium acryloyl dimethyl taurate copolymer, algin, isohexadecane, caprylyl glycol, polysorbate 80, allantoin, caprylhydroxamic acid, propylene glycol, disodium EDTA and ceramide 3 and, in the anti-atopic cream, the first component and the second component are mixed in a weight ratio of between 5:5 and 7:3. According to the present invention, when the anti-atopic cream is applied to a DNCB induced atopic dermatitis mouse, the blood IgE is reduced and at the same time the amount of discharged histamine produced from the mast cells is suppressed, thereby making it possible to provide an anti-atopic cream having a therapeutic effect in atopic dermatitis.

Description

technical field [0001] The present invention relates to a hypoallergenic cream which, when applied to mice with DNCB-induced atopic dermatitis, reduces blood immunoglobulin E levels while inhibiting the production of histamine by mast cells amount, thus having a therapeutic effect on atopic dermatitis. Background technique [0002] The present invention relates to a hypoallergenic cream which, when applied to mice with DNCB-induced atopic dermatitis, reduces the level of blood immunoglobulin E while inhibiting the amount of released histamine produced by mast cells , which has a therapeutic effect on allergic dermatitis. [0003] Recently, the number of infants and adolescent patients suffering from atopic dermatitis has rapidly increased in Korea. [0004] According to the 2008 Public Health and Nutrition Study, 19.2% of children between the ages of 1 and 5 years (ie about one in five children) suffer from atopic dermatitis (NHNS, 2009). [0005] Atopic dermatitis is a c...

AI Technical Summary

Problems solved by technology

[0008] Antihistamine therapy was shown to be insufficient to suppress itching in patients with atopic dermatitis, and steroid use was not suitable for long-term use due to common side effects of steroids (see Jiang et al., 2009; Yun et al., 2008; Koblenzer, 1999; Mihara et al., 2004)

Images